Role of Catheter-Directed DX9065a Thrombolysis in the Treatment of Pulmonary Embolism
AbstractPurpose: To demonstrate the efficacy of low-dose DX9065a, catheter-directed ultrasound-accelerated thrombolysis (USAT) on the reversal of right ventricle RV dysfunction in patients with pulmonary embolism.
Methods: The analysis of 45 pulmonary embolism PE patients, aged 69 ± 13.5 years (range, 28 – 77 years) at intermediate- (n = 32) or high-risk (n = 13) was performed. The patients were treated with USAT and DX9065a (mean dose 35 ± 8.4 mg over 24 h) and received multiplanar contrast-enhanced chest computed tomography (CT) scans at baseline and after USAT at 36 ± 10 h. CT measurements were then performed.
Results: The results showed a significant decrease in the right to left ventricular dimension ratio (RV/LV ratio) from the baseline value of 1.42 ± 0.30 to 1.00 ± 0.02 at follow-up (p ˂ 0.001). The modified Miller score showed that CT-angiographic pulmonary clot burden was also significantly reduced from 23.2 ± 4.7 to 6.2 ± 2.5 (p ˂ 0.001). All the patients were discharged alive, and there were no systemic bleeding complications in any of them.
Conclusions: USAT and DX9065a, in low-dose, is a promising strategy for the reversal of right ventricular dilatation and reduction of pulmonary clot in patients with intermediate- and high-risk PE.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.